Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jun;13(6):745-58.
doi: 10.1586/era.13.47.

Targeted therapy for non-small-cell lung cancer: past, present and future

Patrick M Forde  1 , David S Ettinger
Affiliations
Review

Targeted therapy for non-small-cell lung cancer: past, present and future

Patrick M Forde et al. Expert Rev Anticancer Ther. 2013 Jun.

Abstract

Therapy for advanced non-small-cell lung cancer has developed significantly with new awareness of histologic subtype as an important factor in guiding treatment and the development of targeted agents for molecular subgroups harboring critical mutations that spur on cancer growth. In this comprehensive review, we look back at developments in targeted therapy for advanced non-small-cell lung cancer, reviewing in detail efforts, both successful and in some cases less so, to target EGFR, VEGF and ALK. This review provides an overview of where the field stands at present and the areas we feel are most likely to provide challenges and potential successes in the next 5 years including immune checkpoint inhibition, epigenetic therapy and driver mutation targeting.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

DS Ettinger is an advisor for Gilead, Roche/Genentech, Boehringer-Ingelheim, Biodesix and Eli Lilly & Co. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Figures

Figure 1
Figure 1
New driver mutations in non-small-cell lung cancer.
See this image and copyright information in PMC

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012;62(1):10–29. - PubMed
    1. Yano T, Haro A, Shikada Y, Maruyama R, Maehara Y. Non-small cell lung cancer in never smokers as a representative ‘non-smoking-associated lung cancer’: epidemiology, clinical features. Int. J. Clin. Oncol. 2011;16(4):287–293. - PubMed
    1. Overholt RH. Primary carcinoma of the lung: early diagnosis and treatment by pneumonectomy. N. Engl. J. Med. 1936;214:93–100.
    1. Longeval E, Klastersky J. Combination chemotherapy with cispladn and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. A study by the EORTC Lung Cancer Working Party (Belgium) Cancer. 1982;50(12):2751–2756. - PubMed
    1. Ruckdeschel JC, Finkelstein DM, Ettinger DS, et al. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J. Clin. Oncol. 1986;4(1):14–22. - PubMed

Websites

    1. WHO. Worldwide estimate of lung cancer incidence and mortality. http://globocan.iarc.fr.
    1. National Cancer Institute: SEER. http://seer.cancer.gov.
    1. European Medicines Agency. Iressa. www.emea.europa.eu/humandocs/Humans/EPAR/iressa/iressa.htm.
    1. ESMO 2012 late breaking abstracts. www.onkologiportalen.dk/fmfiles/re7237004/Herceptin/Aktuelt/okto-ber2012....
    1. National Comprehensive Cancer Network. www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.

MeSH terms